Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation.


Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
09 2022
Historique:
received: 05 05 2022
revised: 26 05 2022
accepted: 13 06 2022
pubmed: 21 6 2022
medline: 31 8 2022
entrez: 20 6 2022
Statut: ppublish

Résumé

Covid-19 vaccination is recommended in allogeneic transplant recipients, but many questions remain regarding its efficacy. Here we studied serologic responses in 145 patients who had undergone allogeneic transplantation using in vivo T-cell depletion. Median age was 57 (range 21-79) at transplantation and 61 (range 24-80) at vaccination. Sixty-nine percent were Caucasian. One third each received transplants from HLA-identical related (MRD), adult unrelated (MUD), or haploidentical-cord blood donors. Graft-versus-host disease (GVHD) prophylaxis involved in-vivo T-cell depletion using alemtuzumab for MRD or MUD transplants and anti-thymocyte globulin for haplo-cord transplants. Patients were vaccinated between January 2021 and January 2022, an average of 31 months (range 3-111 months) after transplantation. Sixty-one percent received the BNT162b2 (bioNtech/Pfizer) vaccine, 34% received mRNA-1273 (Moderna), and 5% received JNJ-78436735 (Johnson & Johnson). After the initial vaccinations (2 doses for BNT162b2 and mRNA-1273, 1 dose for JNJ-7843673), 124 of the 145 (85%) patients had a detectable SARS-CoV-2 spike protein (S) antibody, and 21 (15%) did not respond. Ninety-nine (68%) had high-level responses (≥100 binding antibody units [BAU]/mL)m and 25 (17%) had a low-level response (<100 BAU/mL). In multivariable analysis, lymphocyte count less than 1 × 10

Identifiants

pubmed: 35724850
pii: S2666-6367(22)01401-4
doi: 10.1016/j.jtct.2022.06.012
pmc: PMC9213029
pii:
doi:

Substances chimiques

Ad26COVS1 JT2NS6183B
COVID-19 Vaccines 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

618.e1-618.e10

Informations de copyright

Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

J Hematol Oncol. 2021 Oct 24;14(1):174
pubmed: 34689821
Blood Adv. 2022 May 10;6(9):2723-2730
pubmed: 35286374
Cancers (Basel). 2022 Jan 10;14(2):
pubmed: 35053487
Front Oncol. 2021 Sep 06;11:737300
pubmed: 34552880
Biol Blood Marrow Transplant. 2016 Mar;22(3):456-61
pubmed: 26524732
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Leuk Lymphoma. 2022 Feb;63(2):435-442
pubmed: 34643477
Biol Blood Marrow Transplant. 2013 May;19(5):682-91
pubmed: 23142329
Bone Marrow Transplant. 2006 Feb;37(3):307-10
pubmed: 16400339
Clin Microbiol Infect. 2022 Feb;28(2):303.e1-303.e4
pubmed: 34715348
Br J Haematol. 2022 Feb;196(4):884-891
pubmed: 34713441
Blood. 2010 Oct 21;116(16):3080-8
pubmed: 20587785
Leuk Lymphoma. 2013 Jun;54(6):1242-9
pubmed: 23088744
Cancer Cell. 2021 Nov 8;39(11):1448-1449
pubmed: 34717827
Bone Marrow Transplant. 2017 Dec;52(12):1590-1591
pubmed: 28628090
Leuk Lymphoma. 2019 Jul;60(7):1693-1696
pubmed: 30741059
Vaccines (Basel). 2021 Oct 19;9(10):
pubmed: 34696317
Vaccines (Basel). 2022 Jan 21;10(2):
pubmed: 35214617
Transpl Infect Dis. 2022 Apr;24(2):e13792
pubmed: 35030267
J Clin Microbiol. 2020 Sep 22;58(10):
pubmed: 32747400
Blood. 2021 Oct 7;138(14):1278-1281
pubmed: 34339501
Blood Adv. 2019 Jun 25;3(12):1858-1867
pubmed: 31217161
Clin Infect Dis. 2022 Aug 24;75(1):e920-e923
pubmed: 34726754
Am J Hematol. 2021 Nov 1;96(11):E410-E413
pubmed: 34390501
Transplant Cell Ther. 2021 Sep;27(9):788-794
pubmed: 34214738
Semin Hematol. 2016 Oct;53(4):257-266
pubmed: 27788764
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
Leuk Lymphoma. 2011 Feb;52(2):214-22
pubmed: 21142785
Vaccines (Basel). 2022 Mar 14;10(3):
pubmed: 35335079
Transpl Infect Dis. 2022 Jun;24(3):e13828
pubmed: 35324045
Blood Cancer Discov. 2021 Sep 13;2(6):577-585
pubmed: 34778798
Leukemia. 2021 Mar;35(3):850-862
pubmed: 32555371
Curr Oncol. 2022 Jan 13;29(1):337-349
pubmed: 35049704
EBioMedicine. 2021 Dec;74:103705
pubmed: 34861491
Blood. 2011 Dec 8;118(24):6438-45
pubmed: 21976674
Biol Blood Marrow Transplant. 2009 May;15(5):610-7
pubmed: 19361753
Bone Marrow Transplant. 2021 Dec;56(12):3094-3096
pubmed: 34584239
Bone Marrow Transplant. 2016 Jun;51(6):825-32
pubmed: 26901708
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
Transplant Cell Ther. 2022 Mar;28(3):173.e1-173.e6
pubmed: 34954150
Pathog Immun. 2021 Jun 7;6(1):116-134
pubmed: 34136730
Clin Infect Dis. 2020 Nov 5;71(8):e301-e307
pubmed: 31794975
Transplantation. 2017 Jan;101(1):e34-e38
pubmed: 27764032
Leuk Lymphoma. 2020 Dec;61(12):3024-3026
pubmed: 32654572
J Hematol Oncol. 2022 Mar 18;15(1):27
pubmed: 35303906
Br J Haematol. 2022 Mar;196(5):e38-e40
pubmed: 34671982
J Clin Virol. 2020 Aug;129:104480
pubmed: 32505777
Clin Infect Dis. 2012 Nov 15;55(10):1362-70
pubmed: 22903766
Blood. 2022 Jan 6;139(1):134-137
pubmed: 34818411
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Lancet Haematol. 2021 Oct;8(10):e681-e683
pubmed: 34487683
EJHaem. 2021 Jun 01;2(3):520-524
pubmed: 34226903
Blood Cancer J. 2022 Jan 12;12(1):6
pubmed: 35022420
Lancet. 2021 Jul 24;398(10297):298-299
pubmed: 34270933
Vaccines (Basel). 2021 Sep 25;9(10):
pubmed: 34696183
Lancet Haematol. 2021 Aug;8(8):e583-e592
pubmed: 34224668
Biol Blood Marrow Transplant. 2004 Mar;10(3):186-94
pubmed: 14993884
Haematologica. 2022 Aug 01;107(8):1840-1849
pubmed: 34911284
CA Cancer J Clin. 2020 Sep;70(5):349-354
pubmed: 32662880
Am J Hematol. 2022 Jan 1;97(1):30-42
pubmed: 34695229
Biol Blood Marrow Transplant. 2015 Oct;21(10):1839-45
pubmed: 26119367
Leuk Lymphoma. 2009 Nov;50(11):1809-17
pubmed: 19821799
Transplant Cell Ther. 2022 Apr;28(4):214.e1-214.e11
pubmed: 35092892
N Engl J Med. 2016 Sep 8;375(10):944-53
pubmed: 27602666
Haematologica. 2016 May;101(5):634-43
pubmed: 26869630
Vaccines (Basel). 2022 Feb 18;10(2):
pubmed: 35214787
Blood. 2002 Jun 15;99(12):4357-63
pubmed: 12036862
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
J Clin Oncol. 2005 Aug 20;23(24):5728-38
pubmed: 16009946

Auteurs

Ok-Kyong Chaekal (OK)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York; Department of Medicine, Division of Hematology/Oncology, Cell Therapy Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Alexandra Gomez-Arteaga (A)

Department of Medicine, Division of Hematology/Oncology, Cell Therapy Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Zhengming Chen (Z)

Division of Biostatistics, Department of Population Sciences, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Rosemary Soave (R)

Division of Infectious Diseases, Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Tsiporah Shore (T)

Department of Medicine, Division of Hematology/Oncology, Cell Therapy Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Sebastian Mayer (S)

Department of Medicine, Division of Hematology/Oncology, Cell Therapy Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Adrienne Phillips (A)

Department of Medicine, Division of Hematology/Oncology, Cell Therapy Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Jing Mei Hsu (JM)

Department of Medicine, Division of Hematology/Oncology, Cell Therapy Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Alexander Drelick (A)

Division of Infectious Diseases, Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Rosy Priya L Kodiyanplakkal (RPL)

Division of Infectious Diseases, Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Markus Plate (M)

Division of Infectious Diseases, Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Michael J Satlin (MJ)

Division of Infectious Diseases, Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Koen van Besien (K)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York; Department of Medicine, Division of Hematology/Oncology, Cell Therapy Program, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York. Electronic address: Kov9001@med.cornell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH